C4 Therapeutics Inc (NASDAQ:CCCC) shares are trading significantly lower Friday afternoon after the company presented data from Cohort A of its ongoing Phase 1/2 clinical trial of CFT7455.
Cohort A, the first cohort in the clinical trial, explored CFT7455 as a single agent and enrolled five patients with multiple myeloma. The company said that at the time of the data cut-off, two patients remained on therapy, however, all patients have since discontinued treatment.
Related Link: C4 Therapeutics Stock Falls On CFT7455 Dose Limiting Toxicity In Multiple Myeloma Trial
C4 is a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated.
CCCC 52-Week Range: $19.81 - $51.21
According to data from Benzinga Pro, the stock was down 50.8% at $11.27 at time of publication.
Photo: jarmoluk from Pixabay.
